Edition:
India

Walgreens Boots Alliance Inc (WBA.O)

WBA.O on Nasdaq

70.36USD
14 Dec 2017
Change (% chg)

-- (--)
Prev Close
$70.36
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
7,154,356
52-wk High
$88.00
52-wk Low
$63.82

Chart for

About

Walgreens Boots Alliance, Inc. is a holding company. The Company is a pharmacy-led health and wellbeing company. The Company operates through three segments: Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale. The Retail Pharmacy USA segment consists of the Walgreen Co. (Walgreens) business, which... (more)

Overall

Beta: 1.24
Market Cap(Mil.): $78,331.06
Shares Outstanding(Mil.): 1,070.10
Dividend: 0.40
Yield (%): 2.19

Financials

  Industry Sector
P/E (TTM): -- 21.41 16.44
EPS (TTM): -- -- --
ROI: -- 11.88 10.62
ROE: -- 13.57 14.20

Breakingviews - Walgreens gets in early on healthy growth in China

HONG KONG (Reuters Breakingviews) - Walgreens Boots Alliance is positioning itself for future healthy growth in China. On Wednesday, the U.S. drugstore chain said it would pay $416 million for 40 percent of Shanghai-headquartered peer GuoDa. A sensible shake-up of drug distribution and sales by Beijing is spurring consolidation and giving pharmacies a stronger hand. This deal gives Walgreens market insight and could be a springboard for more investment.

07 Dec 2017

Fred's shares hit 18-year low after company pulls dividend

Discount store operator Fred's Inc said on Wednesday it had canceled its quarterly cash dividend and was exploring alternatives for some of its assets, sending its shares plunging 25 percent to their lowest in more than 18 years.

06 Dec 2017

Walgreens to buy 40 percent stake in Chinese pharmacy chain

Walgreens Boots Alliance Inc said it would buy a 40 percent stake in Chinese pharmacy chain operator Sinopharm Holding GuoDa Drugstores Co Ltd, as the U.S. drugstore chain seeks to expand in the country's fast-growing healthcare market.

06 Dec 2017

Walgreens to buy 40 percent stake in Chinese pharmacy chain

Walgreens Boots Alliance Inc said it would buy a 40 percent stake in Chinese pharmacy chain operator Sinopharm Holding GuoDa Drugstores Co Ltd, as the U.S. drugstore chain seeks to expand in the country's fast-growing healthcare market.

06 Dec 2017

UPDATE 1-Walgreens to buy 40 pct stake in Chinese pharmacy chain

Dec 6 Walgreens Boots Alliance Inc said it would buy a 40 percent stake in Chinese pharmacy chain operator Sinopharm Holding GuoDa Drugstores Co Ltd, as the U.S. drugstore chain seeks to expand in the country's fast-growing healthcare market.

06 Dec 2017

Walgreens to buy 40 pct stake in Chinese pharmacy chain

Dec 6 Walgreens Boots Alliance Inc said on Wednesday it would buy a 40 percent minority stake in China National Accord Medicines Corp Ltd's subsidiary Sinopharm Holding GuoDa Drugstores Co Ltd.

06 Dec 2017

BRIEF-Walgreens Boots Alliance To Invest In Chinese Pharmacy Chain GuoDa

* WALGREENS BOOTS ALLIANCE TO INVEST IN CHINESE PHARMACY CHAIN GUODA

06 Dec 2017

CVS likely wants FTC antitrust review, not Justice Department, of Aetna deal

WASHINGTON It is uncertain who in the U.S. government will carry out an antitrust review of CVS Health Corp's deal to buy health insurer Aetna Inc , but the drugstore company is likely hoping the potentially more lenient Federal Trade Commission gets the nod, antitrust experts say. | Video

06 Dec 2017

Fitch Downgrades GNC to 'B-' After Withdrawal of Refinancing Proposal; Outlook Negative

(The following statement was released by the rating agency) NEW YORK, December 05 (Fitch) Fitch Ratings has downgraded GNC Holdings, Inc.'s IDR to 'B-' from 'B' on increased refinancing risk following the announced withdrawal of its proposed refinancing offering. The Negative Outlook reflects Fitch's reduced confidence in GNC's ability to address upcoming maturities ($300 million revolver due September 2018 and $1.1 billion term loan maturity in March 2019) given the termination of its current r

06 Dec 2017

CVS likely wants FTC antitrust review, not Justice Dept, of Aetna deal

WASHINGTON, Dec 5 It is uncertain who in the U.S. government will carry out an antitrust review of CVS Health Corp's deal to buy health insurer Aetna Inc, but the drugstore company is likely hoping the potentially more lenient Federal Trade Commission gets the nod, antitrust experts say.

05 Dec 2017

Earnings vs. Estimates